# Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

> **NCT01274338** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 1673 (actual)

## Conditions studied

- Melanoma of Unknown Primary
- Recurrent Melanoma
- Stage IIIB Cutaneous Melanoma AJCC v7
- Stage IIIC Cutaneous Melanoma AJCC v7
- Stage IV Cutaneous Melanoma AJCC v6 and v7

## Interventions

- **BIOLOGICAL:** Ipilimumab
- **OTHER:** Quality-of-Life Assessment
- **BIOLOGICAL:** Recombinant Interferon Alfa-2b

## Key facts

- **NCT ID:** NCT01274338
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2011-06-17
- **Primary completion:** 2019-02-15
- **Final completion:** 2027-02-02
- **Target enrollment:** 1673 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01274338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01274338, "Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01274338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*